Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Liver Transplantation Plus Chemotherapy Improves 5-Year OS Rate in Patients With CRC Liver Metastases

June 2nd 2024

Integrating liver transplantation into treatment with chemotherapy improved survival at 5 years vs chemotherapy alone in patients with definitively unresectable CRC liver metastases.

OncLive’s May Roundup of Key FDA Approvals in Oncology

May 31st 2024

Here is your guide to important regulatory approvals made by the FDA in May 2024.

Revisit Every OncLive On Air Episode From May 2024

May 30th 2024

In case you missed any, below is a recap of every OncLive On Air episode that aired in May 2024.

FDA Advisory Committee Recommends Approval of Shield Blood Test for CRC Detection in Average-Risk Adults

May 24th 2024

The FDA’s Medical Devices Advisory Committee recommends the approval of the Shield blood test for CRC screening in adults at average risk for CRC.

Dr Bou Farhat on a Retrospective Study of NGS vs IHC Sensitivity for dMMR CRC and Endometrial Cancer

May 22nd 2024

Elias Bou Farhat, MD, discusses an investigation of NGS sensitivity vs standard IHC alone in the assessment of dMMR colorectal cancer or endometrial cancer.

Dr Kasi on the Potential Implications of ctDNA presence in Colorectal Cancer

May 17th 2024

Pashtoon Murtaza Kasi, MD, MS, discusses the potential implications of ctDNA on clinical practice in treating/diagnosing colorectal cancer.

FDA to Hold End-of-Phase 2 Meeting for Botensilimab Plus Balstilimab in R/R mCRC

May 16th 2024

The FDA will hold an end-of-phase 2 meeting to discuss botensilimab plus balstilimab for the treatment of patients with relapsed/refractory metastatic colorectal cancer.

Dr Pederson on Novel Therapies for the Management of Targetable mCRC

May 13th 2024

Katrina S. Pedersen, MD, MS, discusses key updates in the therapeutic landscape for patients with molecularly targetable metastatic colorectal cancer.

Advances in MRD Testing Help Guide Optimal Colorectal Cancer Therapy

May 10th 2024

During an OncLive Peer Exchange, a panel of expert clinicians in CRC discussed studies seeking to further define the role of MRD testing in CRC.

Unmet Needs and Future Perspectives in Colorectal Cancer

May 9th 2024

The panel concludes with perspectives on the future of treatment for patients with colorectal cancer, including unmet needs in the disease space.

FDA Approves Noninvasive Stool RNA Screening Test for CRC

May 7th 2024

The FDA has approved ColoSense for use as a screening test in adults 45 years of age or older who are at average risk of developing colorectal cancer.

Dr Lenz on the Association Between HER2 Expression and Treatment Outcomes in mCRC

May 6th 2024

Heinz-Josef Lenz, MD, FACP, discusses the association between HER2 expression and treatment outcomes in metastatic colorectal cancer.

Trajectory of CRC Treatment Landscape

May 6th 2024

The panelists provide their final thoughts, exploring the prospective treatment landscape for patients with CRC.

EMA Validates MAA for Frontline Nivolumab/Ipilimumab for MSI-H/dMMR mCRC

May 6th 2024

The European Medicines Agency has validated an application for nivolumab plus ipilimumab for frontline MSI-H/dMMR metastatic colorectal cancer.

MRD Testing in CRC: Gaps in our Understanding and Potential Advancements

May 6th 2024

The expert panel continues the discussion with thoughts on gaps in our understanding and application of MRD testing for colorectal cancer and a look to the future, highlighting potential advancements.

Multidisciplinary Care for Patients with CRC

May 2nd 2024

Clinical insights on the roles of various members within a multidisciplinary team involved in the care of patients with colorectal cancer.

Toxicity Considerations and Treatment Decisions in CRC

May 2nd 2024

Experts on colorectal cancer discuss the treatment decision-making process, highlighting the safety profiles of fruquintinib and regorafenib.

Dr Kopetz on the Future Utility of Adagrasib/Cetuximab in KRAS G12C–Mutant CRC

April 30th 2024

Scott Kopetz, MD, PhD, FACP, discusses the potential FDA approval of adagrasib in combination with cetuximab in KRAS G12C-mutatated colorectal cancer.

CIRCULATE-NORTH AMERICA and Barriers to Enrollment

April 29th 2024

Stacey Cohen, MD, discusses the rationale and study design of the phase 2/3 CIRCULATE-NORTH AMERICA study evaluating adjuvant chemotherapy selection based on MRD, and the panel discusses barriers to enrollment.

Recent Data from INTERCEPT and COSMOS-CRC-01 in Colorectal Cancer: Part 2

April 29th 2024

The panel continues its review of data presented on MRD testing in colorectal cancer from the INTERCEPT and COSMOS-CRC-01 studies.